Tye Soon Limited (SGX:BFU)
Singapore · Delayed Price · Currency is SGD 0.3300
0.00 (0.00%)
At close: Aug 8, 2025, 5:00 PM SGT
Intra-Cellular Therapies Income Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 257.16 | 254.4 | 249.32 | 225.33 | 198.24 | Upgrade |
Other Revenue | 0.32 | 0.06 | 0.15 | - | - | Upgrade |
| 257.49 | 254.46 | 249.47 | 225.33 | 198.24 | Upgrade | |
Revenue Growth (YoY) | 1.19% | 2.00% | 10.71% | 13.67% | -10.78% | Upgrade |
Cost of Revenue | 199.87 | 198.93 | 194.93 | 177.17 | 156.74 | Upgrade |
Gross Profit | 57.62 | 55.53 | 54.54 | 48.16 | 41.49 | Upgrade |
Selling, General & Admin | 28.69 | 26.95 | 26.15 | 25.13 | 23.24 | Upgrade |
Other Operating Expenses | 14.25 | 13.63 | 11.59 | 10.29 | 9.45 | Upgrade |
Operating Expenses | 47.78 | 45.24 | 42.46 | 40.12 | 37.57 | Upgrade |
Operating Income | 9.84 | 10.29 | 12.08 | 8.04 | 3.92 | Upgrade |
Interest Expense | -4.25 | -4.43 | -2.39 | -1.68 | -2.43 | Upgrade |
Interest & Investment Income | 0.11 | 0.01 | 0.01 | 0.01 | 0.02 | Upgrade |
Earnings From Equity Investments | - | - | - | 0.05 | 0.05 | Upgrade |
Currency Exchange Gain (Loss) | - | - | -1.11 | -0.31 | -0.33 | Upgrade |
Other Non Operating Income (Expenses) | - | - | - | 0.07 | 0.12 | Upgrade |
EBT Excluding Unusual Items | 5.7 | 5.87 | 8.59 | 6.17 | 1.36 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | -0.11 | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | -0.02 | -0.03 | 0 | Upgrade |
Other Unusual Items | - | - | - | 0.11 | 0.98 | Upgrade |
Pretax Income | 5.7 | 5.87 | 8.58 | 6.13 | 2.34 | Upgrade |
Income Tax Expense | 1.42 | 1.55 | 2.17 | 1.58 | 1.06 | Upgrade |
Earnings From Continuing Operations | 4.28 | 4.32 | 6.41 | 4.55 | 1.28 | Upgrade |
Minority Interest in Earnings | -0.05 | -0.07 | -0.13 | -0.08 | -0.05 | Upgrade |
Net Income | 4.24 | 4.25 | 6.28 | 4.47 | 1.22 | Upgrade |
Net Income to Common | 4.24 | 4.25 | 6.28 | 4.47 | 1.22 | Upgrade |
Net Income Growth | -0.42% | -32.26% | 40.54% | 264.95% | 441.59% | Upgrade |
Shares Outstanding (Basic) | 87 | 87 | 87 | 87 | 87 | Upgrade |
Shares Outstanding (Diluted) | 87 | 87 | 87 | 87 | 87 | Upgrade |
EPS (Basic) | 0.05 | 0.05 | 0.07 | 0.05 | 0.01 | Upgrade |
EPS (Diluted) | 0.05 | 0.05 | 0.07 | 0.05 | 0.01 | Upgrade |
EPS Growth | -0.42% | -32.26% | 40.54% | 264.95% | 441.75% | Upgrade |
Free Cash Flow | 0.29 | -1.07 | 3.35 | 2.61 | 20.74 | Upgrade |
Free Cash Flow Per Share | 0.00 | -0.01 | 0.04 | 0.03 | 0.24 | Upgrade |
Dividend Per Share | 0.019 | 0.013 | 0.013 | 0.009 | - | Upgrade |
Dividend Growth | 50.04% | - | 50.00% | - | - | Upgrade |
Gross Margin | 22.38% | 21.82% | 21.86% | 21.37% | 20.93% | Upgrade |
Operating Margin | 3.82% | 4.04% | 4.84% | 3.57% | 1.98% | Upgrade |
Profit Margin | 1.65% | 1.67% | 2.52% | 1.98% | 0.62% | Upgrade |
Free Cash Flow Margin | 0.11% | -0.42% | 1.34% | 1.16% | 10.46% | Upgrade |
EBITDA | 10.23 | 10.66 | 12.45 | 8.39 | 4.3 | Upgrade |
EBITDA Margin | 3.97% | 4.19% | 4.99% | 3.72% | 2.17% | Upgrade |
D&A For EBITDA | 0.39 | 0.38 | 0.36 | 0.35 | 0.38 | Upgrade |
EBIT | 9.84 | 10.29 | 12.08 | 8.04 | 3.92 | Upgrade |
EBIT Margin | 3.82% | 4.04% | 4.84% | 3.57% | 1.98% | Upgrade |
Effective Tax Rate | 24.86% | 26.41% | 25.31% | 25.84% | 45.38% | Upgrade |
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.